215 related articles for article (PubMed ID: 17922046)
41. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
Rossi E; Villanacci V; Bassotti G; Donato F; Festa A; Cengia G; Grisanti S; Cestari R
Histopathology; 2010 Jul; 57(1):81-9. PubMed ID: 20557373
[TBL] [Abstract][Full Text] [Related]
42. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C
Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492
[TBL] [Abstract][Full Text] [Related]
44. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
[TBL] [Abstract][Full Text] [Related]
45. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
46. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.
Nielsen KV; Ejlertsen B; Møller S; Jensen MB; Balslev E; Müller S; Knoop A; Mouridsen HT
Mol Oncol; 2012 Feb; 6(1):88-97. PubMed ID: 22153616
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.
Jones SE; Collea R; Paul D; Sedlacek S; Favret AM; Gore I; Lindquist DL; Holmes FA; Allison MAK; Brooks BD; Portillo RM; Vukelja SJ; Steinberg MS; Stokoe C; Crockett MW; Wang Y; Asmar L; Robert NJ; O'Shaughnessy J
Lancet Oncol; 2013 Oct; 14(11):1121-1128. PubMed ID: 24007746
[TBL] [Abstract][Full Text] [Related]
48. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
49. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Harris LN; Broadwater G; Abu-Khalaf M; Cowan D; Thor AD; Budman D; Cirrincione CT; Berry DA; Winer EP; Hudis CA; Hayes DF; Friedman P; Ellis M; Dressler L
J Clin Oncol; 2009 Jul; 27(21):3430-6. PubMed ID: 19470942
[TBL] [Abstract][Full Text] [Related]
50. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
51. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
[TBL] [Abstract][Full Text] [Related]
52. Topoisomerase IIalpha gene (TOP2A) amplification and deletion in cancer--more common than anticipated.
Järvinen TA; Liu ET
Cytopathology; 2003 Dec; 14(6):309-13. PubMed ID: 14632727
[TBL] [Abstract][Full Text] [Related]
53. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
[TBL] [Abstract][Full Text] [Related]
54. [Abnormality of TOP2A expression and its gene copy number variations in neuroblastic tumors].
Chen JM; Zhou CJ; Ma XL; Guan DD; Yang LY; Yue P; Gong LP
Zhonghua Bing Li Xue Za Zhi; 2016 Nov; 45(11):748-754. PubMed ID: 27821228
[No Abstract] [Full Text] [Related]
55. [Specific features of gene amplification on the long arm of chromosome 17 in different molecular genetic subtypes of breast cancer].
Zavalishina LE; Danilova NV; Matsionis AE; Pavlenko IA
Arkh Patol; 2014; 76(2):8-12. PubMed ID: 25051718
[TBL] [Abstract][Full Text] [Related]
56. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
Partanen L; Staaf J; Tanner M; Tuominen VJ; Borg Å; Isola J
Genes Chromosomes Cancer; 2012 Sep; 51(9):832-40. PubMed ID: 22585709
[TBL] [Abstract][Full Text] [Related]
57. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
[TBL] [Abstract][Full Text] [Related]
58. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond.
Jacot W; Fiche M; Zaman K; Wolfer A; Lamy PJ
Biochim Biophys Acta; 2013 Aug; 1836(1):146-57. PubMed ID: 23628726
[TBL] [Abstract][Full Text] [Related]
59. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer.
Moelans CB; de Weger RA; van Blokland MT; van der Wall E; van Diest PJ
Mod Pathol; 2010 Jan; 23(1):62-70. PubMed ID: 19767729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]